RA CAPITAL MANAGEMENT, L.P. purchased $1.4M of ARTV (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 160,354 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.93 ($8.93–$8.95, $1.43M total) across 2 trades over 2026-07-16 to 2026-07-17.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jul 20, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 10:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bullish
medium confidence
Mentioned
$ARTV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBullishLow
01

Why it matters

The newest fact is the specific open-market purchase amount, share count, and price range, which may modestly influence sentiment but does not change ARTV’s fundamentals based on the provided text.

02

Market read

Traders may note the disclosed buying as a small sentiment input, but there is no accompanying catalyst in the text.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article does not provide intent, holding horizon, or whether the fund’s stake is part of a broader strategy.

Relevance 7/10Novelty 4/10Timing: Filed on 2026-07-20, covering purchases executed 2026-07-16 to 2026-07-17.

Background

The article is a SEC Form 4 insider transaction disclosure, where RA Capital Management, L.P. is listed as a director and 10% owner with an indirect position in Artiva Biotherapeutics.

Company-level read

Ticker impact

$ARTVBullishMedium confidence
Context

RA Capital Management, L.P. reported an open-market purchase of 160,354 shares of Artiva Biotherapeutics (ARTV) for about $1.43M on 2026-07-16 to 2026-07-17.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 provides a fresh, specific transaction size and price range, but it does not include new company guidance, trial results, contracts, or regulatory actions.

Market effects

No direct sector read-through; this is a single-issuer Form 4 transaction.

None indicated.

None indicated.

Counterpoint

Indirect purchases by a large holder can reflect portfolio rebalancing or liquidity needs rather than a conviction signal about near-term fundamentals.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 disclosure, ticker ARTV.

  • RA Capital Management, L.P.

    Reported the indirect open-market purchase totaling about $1.43M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.